Cloud computing is the secret to Cloud Pharmaceuticals’ drug discovery

October 4, 2016 Christoph Graener

Cloud Pharmaceuticals COO Don Van Dyke speaks with Informa Pharma Intelligence at BioPharm America 2016 about how the company uses cloud computing to accelerate the discovery and design of novel small-molecule drug candidates in therapeutic areas such as cancer, inflammatory disease, infectious disease and central nervous system disorders. Van Dyke discusses how an ongoing partnership helped Cloud develop its technology for creating drug candidates that can pervade the blood-brain barrier and the company’s virtual model, in which it performs the computational chemistry and partners out bench preclinical processes.


Interviewer: Joe Haas – Senior Writer, The Pink Sheet, Informa
Inerviewee: Don Van Dyke – COO, Cloud Pharmaceuticals

Previous Article
Novel approach to CAR T cell therapy at UPenn Center for Cellular Immunotherapies

Avery Posey outlines his work in CAR T therapy at the Center for Cellular Immunotherapies at UPenn during a...

Next Article
Maximizing your social media presence

A diverse group of industry professionals discuss how they use social media in their daily business practic...